African-Americans show poorer outcomes for low-risk prostate cancer

This article originally appeared here.
Share this content:
Racial Discrepancy in Oncologic Outcomes for Low-Risk PCa
Racial Discrepancy in Oncologic Outcomes for Low-Risk PCa

(HealthDay News) -- Among men with very-low-risk prostate cancer (PCa) who meet criteria for active surveillance but undergo radical prostatectomy, African-American race is associated with poorer outcomes, with higher rates of disease upgrading and adverse pathology, according to a study published online June 17 in the Journal of Clinical Oncology.

To examine whether race-based health disparities exist among men with very-low-risk PCa who undergo prostatectomy, Debasish Sundi, M.D., from Johns Hopkins University in Baltimore, and colleagues studied 1,801 men (256 African-American, 1,473 white, and 72 others) who met National Comprehensive Cancer Network criteria for very low-risk PCa. Comparisons were made by racial group with regards to presenting characteristics, pathologic data, and cancer recurrence.

The researchers found that more adverse pathologic features at prostatectomy and poorer oncologic outcomes were seen for African-American men with very-low-risk PCa. For African-American men, there was an increased likelihood of experiencing disease upgrading at prostatectomy (27.3 versus 14.4 percent; P < 0.001); positive surgical margins (9.8 versus 5.9 percent; P = 0.02); and higher Cancer of the Prostate Risk Assessment Post-Surgical scoring system scores. African-American race was an independent predictor of adverse pathologic features and pathologic upgrading (odds ratio, 3.23 and 2.26, respectively), on multivariate analysis.

"African-American men with very-low-risk PCa should be counseled about increased oncologic risk when deciding among their disease management options," the authors write.

Full Text

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs